US Approval For Key Production Site Seen Lifting Lupin’s Growth
Executive Summary
Lupin, one of India’s top five drug makers by sales, has reported disappointing second quarter earnings. But investors are looking beyond those numbers and hoping the US FDA’s green light for the firm’s main exporting plant in Goa will increase generic drug approvals and accelerate growth.